NeoPharm to Present LErafAON-ETU Preliminary Phase I Data at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

NeoPharm, Inc. (Nasdaq/NM:NEOL):
Who/What: NeoPharm, Inc. (Nasdaq/NM:NEOL) LErafAON-ETU poster
presentation

Why: Preliminary Phase I Results of NeoPharm's NeoLipid(R)
Formulation of c-raf Antisense Oligonucleotide

Where: AACR-NCI-EORTC International Conference on Molecular Targets
and Cancer Therapeutics - Discovery, Biology, and Clinical
Applications
November 14-18, 2005
Pennsylvania Convention Center
Hall C
Philadelphia, Pennsylvania

When: General Poster Session A
Biological Therapeutic Agents: Antisense Oligonucleotides
Tuesday, November 15, 2005
12:30 p.m. - 2:30 pm
5:30 p.m. - 7:30 p.m.

Title: A Phase I Study of an Easy-To-Use Formulation of Liposome
Entrapped c-raf Antisense Oligonucleotide (LErafAON-ETU) in
Patients with Advanced Cancer

Authors: Michael S. Gordon, David S. Mendelson, Heidi Block,
Sylvan B. Green, Kristen Parker, Amy Y. Grahn,
Vincent S. Shu, Patrick Cullinan,
Daniel D. von Hoff, Jeffrey W. Sherman

About NeoPharm, Inc.

NeoPharm, Inc., based in Waukegan, Illinois, is a publicly tradedbiopharmaceutical company dedicated to the research, development andcommercialization of new and innovative cancer drugs for therapeuticapplications. The Company has a portfolio of cancer compounds invarious stages of development. Additional information can be obtainedby visiting NeoPharm's Website at www.neophrm.com.

Forward Looking Statements - This press release contains"forward-looking statements" within the meaning of Section 27A of theSecurities Act of 1933 and Section 21E of the Securities Exchange Actof 1934. The Company has tried to identify such forward-lookingstatements by use of such words as "expects," "intends," "hopes,""anticipates," "believes," "could," "may," "evidences" and"estimates," and other similar expressions, but these words are notthe exclusive means of identifying such statements. Such statementsinclude, but are not limited to, any statements relating to theCompany's drug development program, including, but not limited toclinical studies involving LErafAON-ETU, and any other statements thatare not historical facts. Such statements involve risks anduncertainties, including, but not limited to, those risks anduncertainties relating to difficulties or delays in financing,development, testing, obtaining regulatory approval, production andmarketing of the Company's drug and non-drug compounds, including, butnot limited to, LErafAON-ETU, uncertainty regarding the availabilityof third party production capacity, unexpected adverse side effects orinadequate therapeutic efficacy of the Company's drug and non-drugcompounds, including, but not limited to, LErafAON-ETU, that couldslow or prevent products coming to market, uncertainty regarding theCompany's ability to market its drug and non-drug products, including,but not limited to, LErafAON-ETU, the uncertainty of patent protectionfor the Company's intellectual property or trade secrets, including,but not limited to, LErafAON-ETU, and other risks detailed from timeto time in filings the Company makes with the Securities and ExchangeCommission including its annual reports on Form 10-K and quarterlyreports on Forms 10-Q. Such statements are based on management'scurrent expectations, but actual results may differ materially due tovarious factors, including those risks and uncertainties mentioned orreferred to in this press release. Accordingly, you should not rely onthese forward-looking statements as a prediction of actual futureresults.